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Abstract
Background: BCA2 is an E3 ligase linked with hormone responsive breast cancers. We have demonstrated
previously that the RING E3 ligase BCA2 has autoubiquitination activity and is a very unstable protein. Previously,
only Rab7, tetherin, ubiquitin and UBC9 were known to directly interact with BCA2.
Methods: Here, additional BCA2 binding proteins were found using yeast two-hybrid and bacterial-II-hybrid
screening techniques with Human breast and HeLa cDNA libraries. Co-expression of these proteins was analyzed
through IHC of TMAs. Investigation of the molecular interactions and effects were examined through a series of in
vivo and in vitro assays.
Results: Ten unique BCA2 interacting proteins were identified, two of which were hHR23a and 14-3-3sigma. Both
hHR23a and 14-3-3sigma are co-expressed with BCA2 in breast cancer cell lines and patient breast tumors (n =
105). hHR23a and BCA2 expression was significantly correlated (P = < 0.0001 and P = 0.0113) in both nucleus and
cytoplasm. BCA2 expression showed a statistically significant correlation with tumor grade. High cytoplasmic
hHR23a trended towards negative nodal status. Binding to BCA2 by hHR23a and 14-3-3sigma was confirmed in
vitro using tagged partner proteins and BCA2. hHR23a and 14-3-3sigma effect the autoubiquitination and auto-
degradation activity of BCA2. Ubiquitination of hHR23a-bound BCA2 was found to be dramatically lower than that
of free BCA2, suggesting that hHR23a promotes the stabilization of BCA2 by inactivating its autoubiquitination
activity, without degradation of hHR23a. On the other hand, phosphorylated BCA2 protein is stabilized by
interaction with 14-3-3sigma both with and without proteasome inhibitor MG-132 suggesting that BCA2 is
regulated by multiple degradation pathways.
Conclusions: The interaction between BCA2 and hHR23a in breast cancer cells stabilizes BCA2. High expression of
BCA2 is correlated with grade in breast cancer, suggesting regulation of this E3 ligase is important to cancer
progression.
Background
Breast Cancer Associated gene 2( B C A 2 )w a sf i r s ti d e n -
tified in an effort to investigate drivers of breast cancer
via the subtractive hybridization [1]. These studies
aimed to identify differentially expressed genes between
Hs578Bst and Hs578T mammary epithelial cell lines
derived from adjacent normal and cancerous tissues
respectively [1]. These analyses revealed 950 cDNAs
enriched in breast cancer cells [1]. Twenty-eight of the
cDNAs were novel genes, including BCA2, a 304 amino
acid protein encoding a RING H2-domain [2]. BCA2 is
located in a chromosomal region known to be up-regu-
lated in breast cancers as well as a region of genomic
instability enriched in cancer driver genes [3]. A number
of RING E3 ligases have both oncogenic and tumor sup-
pressing roles in cancer processes, notably MDM2,
responsible for regulation of p53 [4]; BRCA1/BARD1,
involved in DNA repair [5]; and cCbl, which is responsi-
ble for the internalization and degradation of EGFR [6].
BCA2 contains three domains, the amino-terminal
BCA2 Zinc-Finger (BZF) domain, the AKT phosphoryla-
tion domain, and the carboxy-terminal RING H2 domain
(Figure 1A) [7,8]. BCA2’s RING domain confers autoubi-
quitination activity, consistent with other E3 ubiquitin
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Touted as the “kiss of death” for proteins, ubiquitin is a
highly conserved, 7 kDa protein modifier which targets
proteins for proteasomal degradation. Ubiquitin conjuga-
tion to target proteins involves a number of well-coordi-
nated steps, catalyzed by three enzyme types [11-14].
“Ubiquitination” has long had a negative connotation and
in the past has been solely associated with the proteasome
system. A staggering majority of enzymes that make up
the UPS are particularly susceptible and seemingly promis-
cuously degraded not only through the actions of another
ubiquitin ligase, trans-ubiquitination, but also through
Figure 1 BCA2 is co-expressed with and binds to both hHR23a and 14-3-3s.[ A] The bolded black amino acids represent key residues
which are imperative to the structural integrity of the BZF and RING domains. The bolded yellow residues indicate amino acids which have
been modified to alanine by site-directed mutagenesis. The BZF domain (blue) binds ubiquitin and is also the site of BCA2 auto-ubiquitination
(ubiquitinated lysine residues are shown in red). The AKT domain (green) is site of AKT-mediated phosphorylation of BCA2, predicted by in silico
analysis. Serine residues (yellow) are likely phosphorylated, and have been mutated to alanine in the BCA2 S132, 133A mutant. The RING domain
(orange) is BCA2 autoubiquitination. The yellow cysteine residues were mutated to alanine to create ligase-dead BCA2 RING mutant. [B]
Immunoblots of lysates from HEK293T cells which were co-transfected with GST-tagged BCA2, BZF (C22/25A), S132/133A, RING (C228/231A) or
GST-empty vector along with myc/his-tagged hHR23A. The top panel shows the result of GST-pulldown for BCA2, probed for myc-hHR23a.
Whole cell GST blots are shown at 2 different exposures due to the differences in expression between GST-tagged BCA2 variants or GST alone,
where the expression is substantially higher, and thus required a lower exposure. The difference in hHR23a binding is not a result of hHR23a
expression, as lanes show equal loading for hHR23a and tubulin. [C] BCA2 binds to GST-tagged 14-3-3s from bacterial cell lysates. Purified
recombinant wild-type BCA2 (lane 2) as well as the RING (lane 8) mutant (mt) bind to 14-3-3s (even lanes) but not the GST- alone protein (odd
lanes). [D] Immunoblots of lysates from HEK293T cells which were co-transfected with FLAG-tagged BCA2 along with Xpress-tagged 14-3-3s.
BCA2 was introduced at 1 μg, 2 μgo r3μg of plasmid DNA, while 14-3-3s vector concentration was kept constant. The top panel shows
increasing concentration of BCA2, the middle panel indicates a progressive decrease in expression of 14-3-3s. b-Actin levels indicate decreasing
14-3-3s is not an artefact of mis-loading (bottom part). [E] Immunoblots of lysates from HEK293T cells which were co-transfected with GST-
tagged BCA2 along with myc/his-tagged hHR23A. BCA2 was introduced to the system in an increasing concentration, 1 μg, 2 μgo r3μg, while
the concentration of hHR23a vector was kept constant. The top panel shows increasing concentration of BCA2, the middle panel does not show
any decrease in the expression of hHR23a, indicating there is no degradation. b-Tubulin levels indicate that the blot is equally loaded (third
panel).
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and Ciechanover [15] discussed the mechanisms of regula-
tion for E3 ligases. Both RING- and HECT-type ubiquitin
ligases undergo various modifications and have multiple
mechanisms that act to stabilize and/or activate these
dynamic enzymes. Included in E3 modulation are sub-
strate binding, phosphorylation and other post-translation
modifications such as auto- or trans-ubiquitination for
both proteolytic and non-proteolytic fates [15].
The wild-type BCA2 protein is unstable due to its auto-
ubiquitination activity mediated by its RING domain.
Substantial protein degradation has been shown in vivo
and in vitro for the wild-type protein; however ligase-
dead BCA2 variants showed no signs of degradation
[2,7]. We and other have previously investigated partner
of BCA2. Proteins shown to directly interact with BCA2
are Rab7, tetherin, ubiquitin and UBC9 [7,16-18]. In this
study we identified additional BCA2 binding proteins.
Ten new BCA2 interacting proteins were identified, two
of which were hHR23a and 14-3-3s. These proteins were
chosen for further study as hH23Ra is a known chaper-
one in the ubiquitin-proteasome system (UPS) [19].
While 14-3-3s, a multifunctional adaptor has been
shown to have a role in many cancers including breast
cancer [20]. The effects of hHR23a and 14-3-3s on the
stability and the autoubiquitination activity of BCA2, as
well as co-expression of BCA2 and partner proteins in
breast cancer were examined.
Methods
Antibodies
For Immunoblotting, the mouse monoclonal anti-FLAG
(M2), anti-GST-2, anti-HA (HA-7), and anti-b-actin (AC-
15) antibodies were purchased from Sigma-Aldrich Corp,
(St. Louis, MO, USA). The monoclonal anti-polyhistidine
(AD1.1.10) antibody was from R&D Systems (Minneapolis,
MN, USA). The monoclonal anti-c-Myc (9E10) antibody
was from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Monoclonal anti-XPRESS antibody and mouse anti-
b-Tubulin antibody were purchased from Invitrogen
(Carlsbad, CA, USA). Monoclonal antibodies specific to
hHR23a (ab55725) and 14-3-3s (1.N.6) were purchased
from abcam (Cambridge, MA, USA). Horseradish peroxi-
dase-conjugated antimouse IgG secondary and Horserad-
ish peroxidase-conjugated antimouse IgG secondary
antibodies were from Promega (Madison, WI, USA).
For immunofluorescence (IF), primary antibodies for
BCA2 and 14-3-3s were used at 1 in 100 dilution, while
hHR23a was used at 1 in 50 dilution. Secondary antibo-
dies for IF, FITC-AffiniPure Goat Anti-Mouse IgG (H+L)
and Cy3-AffiniPure Goat Anti-Rabbit IgG (H+L), were
from Jackson ImmunoResearch Laboratories Inc. (West
Grove, PA, USA).
For immunohistochemistry (IHC), all primary antibo-
dies were used at dilutions of 1 in 100. Secondary antibo-
dies for IHC were from VECTOR laboratories
(Burlington, ON, Canada), biotinylated anti-mouse IgG
(H+L) or biotinylated anti-rabbit IgG (H+L) were used at
a dilution of 1-200.
Vectors and cloning
The hHR23a construct was created by PCR amplifying
from a cDNA library using the forward primer 5’-
GACTGGATCCATGGCCGTCACCATCACGCTC-3’
which contains a BamHI restriction site, and the reverse
primer 5’-GACTCTCGAGCGCTCGTCATCAAAGTTCT
CACTC-3’ containing an XhoI restriction site. PCR frag-
ments and pSG5-myc/his backbone were digested with
BamHI and XhoI and transformed into cloning cells.
14-3-3s construct was created by cutting the 14-3-3s
gene via restriction digest from a pre-existing bacterial
expression vector pET100 containing the XPRESS-expres-
sion tag. AKT vectors were generously donated to our
laboratory [8]. FLAG BCA2 vectors are as described [7].
GST-tagged BCA2 constructs are in the pEBG backbone,
and were cut in from the pCMV constructs previously
created [7].
Bacteria- and yeast -II-hybrid screening
Bacteria-II hybrid screening followed Stratagene Bacter-
ioMatch protocol. BCA2 bait vector was created by cut-
t i n gF L A G - t a g g e dB C A 2f r o mp C M V - T a g 2 Bv e c t o r
(previously described [7]) with restriction enzymes NotI
and XHoI and ligating into the pBT vector. cDNA target
library, in the pTRG vector, was derived from human
breast cells pooled from 10 donors between 33 to 88
years. The selection of positive transformants was
mediated by X-Gal indicator plates and blue and white
screening.
Bait vector for yeast-II-hybrid screening was created by
cutting the BCA2 construct from BCA2-containing
pCMV-Tag-2B [7] with BamHI and SalI and ligating into
the pSOS vector. Target library in pMyr, containing a
plasma membrane localizing myristolation signal, was cre-
ated from HeLa cells according to the CytoTrap protocol
(Agilent Technologies Inc., Wilmington, DE, USA). Selec-
tion of positive clones was mediated through the tempera-
ture sensitive activation of the RAS-pathway by
recruitment of SOS-tagged bait which allows yeast growth.
Cell culture, transfection and protein lysis
Breast carcinoma cell lines BT474, MCF7, MDA MB 231,
MDA MB 435, MDA MB 436 and MDA MB 453 as well
as HEK293T cells were grown in DMEM with 10% FBS
(Invitrogen) and 1% penicillin/streptomycin (Invitrogen),
at 37°C and 5.0% CO2. For transfection in HEK293T
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concentration. Cells were allowed to settle overnight
prior to transfection. Transfections were performed using
Lipofectamine 2000 transfection reagent (Invitrogen)
according to the manufacturer’s instructions.
Cells were washed and harvested in PBS, then lysed
using lysis buffer containing 1% Nonidet P40 with protei-
nase inhibitors (1 mg/ml pepstatin A, 5 mg/ml leupeptin,
0.5 M EDTA, 1.6 mg/ml aprotinin, 100 mM PMSF). Pro-
tein quantitation was done by Bradford assay (BioRad,
Hercules, CA, USA).
GST-pulldown and co-immunoprecipitations
Mammalian cells were lysed in NP-40 Lysis buffers
without EDTA, for bacterial cells; lysis in PBS occurred
by sonication using 3 rounds of 5 × 1 seconds pulses on
ice. Immunoprecipitations were performed using 25 μl
of sepharose beads (GE Healthcare, Pittsburgh, PA) per
sample. Whole cell lysates (WCL) were added to beads
at protein concentrations between 0.3 mg to 1 mg for
mammalian cell lysates. For bacterial lysates, protein
concentration was determined by western blot prior to
pulldown.
For co-immunoprecipitations (Co-IP), 250-500 μg of cell
lysates were used per sample. Lysates (3-5 ug/sample)
were incubated with antibodies overnight at 4°C with gen-
tle agitation. Protein A/G beads (Santa Cruz) (20 ul/tube)
were aliquoted to microcentrifuge tubes, followed by the
addition of antibody conjugated lysates.
For both GST-pulldowns and Co-IPs, beads and lysates
were incubated at 4°C for 1 hour with constant agitation.
Washed sample were boiled for 10 minutes at 95°C in 1 ×
Sodium Dodecylsulfate (SDS) loading buffer.
SDS-PAGE and western blotting
Proteins (25-50 ug) were resolved on 12% SDS denaturing-
polyacrylamide gels and transferred to nitrocellulose mem-
branes (BioRad). Following transfer membranes are transi-
ently stained with 1 × Ponseau stain to visualize proteins
loading. Blots were blocked in 5% skim-milk powder in
TBST (TBS buffer containing 1% Tween) for 1 hour at
room-temperature, incubated with primary antibodies
overnight at 4°C, washed in TBST, and then incubated
with secondary antibodies, HRP-conjugated anti-mouse or
anti-rabbit (Promega) secondary antibodies, for 1 hour at
room-temperature. Following washes in TBST, proteins
were visualized by addition of Chemi-luminescence
reagent, and exposed to X-Ray film (VWR, Radnor, PA,
USA). Blots were scanned and quantified using ImageJ
ver. 1.44 [21].
Immunofluorescence
Immunofluorescence was performed on cells grown on
Lab-Tek Chamber slides (Fisher Scientific, Rochester
NY, USA). Cells were fixed in 4% paraformaldehyde
(PFA) and blocked using normal goat serum (Jackson
ImmnoResearch Laboratories) for a minimum of 1 hour
at room temperature. Sections were incubated with pri-
mary antibodies overnight at 4°C, in a dark container.
The next morning slides were washed then incubated
with fluorescence-conjugated secondary antibodies for
an hour at room temperature in a dark container. After
washing, slides were mounted using with DAPI (Vecta-
shield mounting medium, VECTOR Laboratories Inc,
Burlingame CA, USA), edges of the coverslip were then
sealed.
Tissue microarrays
Tissue microarrays were generously donated by the
Department of Anatomic Pathology at Sunnybrook
Health Sciences Centre. In accordance with ethics pro-
tocols, specimens were stripped of all patient identifiers
and blinded. Arrays were assembled using paraffin-
embedded breast cancer tissues which had been pre-
viously analyzed for tumor areas by pathologists. Two
master blocks, 105 cases total, were used to produce
serial sections for staining. Blocks contained either 50 or
55 cases of 1.0 mm cores in triplicate. Slide sections
were cut to a thickness of 5 μm, and mounted on PSA
4 × Slides (Leica Biosystems Richmond Inc, Richmon
IL, USA), followed by drying at 60°C for 1 hour.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-
embedded tumor sections. Slides were de-waxed and re-
hydrated by sequential baths in Xylene, ethanol and PBS.
Antigen unmasking occurred though pressure cooking
slides in citrate buffer (pH 6.0). Slides were processed with
H2O2 for 30 minutes and were blocked in normal goat
serum (NGS) (Jackson ImmnoResearch Laboratories), for
1 hour at room temperature. Slides were incubated with
primary antibodies overnight at 4°C. Secondary biotiny-
lated antibodies were applied for 1 hour at room tempera-
ture. ABC complex (Vectastain ABC kit, VECTOR
Laboratories) was applied to sections for 30 minutes at
room temperature, followed by DAB (Peroxidase Substrate
Kit- DAB, VECTOR Laboratories). Slides were treated
with DAB for approximately 2-3 minutes then counter-
stained with hemotoxylin for 30-45 seconds. Slides were
dehydrated prior to mounting using Cytoseal XYL (VWR).
Results
Binding partners of BCA2
Bacteriomatch bacterial-II-hybrid and Cytotrap yeast-II-
hybrid (Agilent) techniques were used to identify partner
proteins of BCA2. BCA2, cloned into pBT, for bacterial
screening or pSOS, for yeast screening, was used as bait to
isolate potential partners from a pTRG breast tissue
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Novel positive clones identified by this both yeast and bac-
teria screens are listed in Table 1. Proteins of interest were
those which affect the stability of their partner proteins.
Both hHR23a, a component of the UPS, and 14-3-3s,
which binds partner proteins through AKT phosphoryla-
tion sites, were selected for further study. The interaction
of BCA2 with ha-c-Ras, inidicated that the yeast screening
system worked optimally and serves as an internal positive
control, as Ras is a down-stream component of SOS, and
is an anticipated interaction.
BCA2 binds hHR23a and 14-3-3s
To validate BCA2 interactions with putative partner pro-
teins, GST-tagged BCA2, along with BZF, S132, 133A and
RING mutants as well as the GST control were co-trans-
fected into HEK293T cells with myc-hHR23a. Cell lysates
subjected to GST-pulldowns, interactions were visualized
though Western blotting using myc antibodies. As shown
in Figure 1B, hHR23a was bound by all tested mutants of
BCA2 as well as wild-type protein (lanes 1-4, top panel),
but not by the GST control (lane 5, top panel). This indi-
cated a specific interaction of hHR23a with BCA2.
hHR23a protein bands in BZF and RING mutants lanes
(Figure 1B, lanes 2 and 4, top panel) appear to have higher
intensity than BCA2 and S132, 133A mutant lanes (Figure
1B, lanes 1 and 3, top panel), this observation likely is to
due to the elevated cellular expression of the RING and
BZF mutants of BCA2.
BCA2 interacted with 14-3-3s by GST-pull-down
assay. Recombinant Flag-BCA2 was incubated with
sepharose-immobilized GST control or GST-14-3-3s.
Immunoblot shown in Figure 1C, indicated that the wild-
type BCA2 and BCA2 RING mutant bound 14-3-3s spe-
cifically (lanes 2 and 8). There was no interaction with
the GST control protein (Figure 1C, lanes 1 and 7).
Moreover, it appeared that the disruption of the BZF
domain or the AKT domain abolished binding with 14-3-
3s. This suggested that that these domains are important
to BCA2 interaction with 14-3-3s (Figure 1C, lanes 3-6).
14-3-3s but not hHR23a is a substrate of BCA2
Both hHR23a and 14-3-3s were investigated as potential
substrates of BCA2 E3 activity. An increasing amount of
Flag-BCA2 (1.0 μg-3.0 μg plasmid DNA) was co-trans-
fected into HEK293T cells along with a constant con-
centration of 14-3-3s (1.0 μg) (Figure 1D). Samples
were analyzed by Western blotting, Figure 1D showed
that increased amount of expressed BCA2 inversely cor-
related with the expression of 14-3-3s protein. This
decreased 14-3-3s expression in relation to BCA2
expression suggested that 14-3-3s may be signaled for
degradation by BCA2 ligase activity.
To investigate the ability of BCA2 to regulate hHR23a,
we examined whether hHR23a would be degraded upon
interaction with BCA2 (Figure 1E). A stable concentra-
tion of hHR23a (1.0 μg) plasmid DNA and an increasing
concentration of BCA2 (1.0 μg-3.0 μg) plasmid DNA
were co-transfected into HEK293T cells and visualized
by immunoblotting. Figure 1E showed the expression of
hHR23a was not decreased in relation to increasing
BCA2 expression. This suggested that hHR23a is not a
substrate for BCA2-mediated degradation. However, we
noticed that hHR23a expression is more robust where
BCA2 protein levels were elevated. This indicated that
while not poly-ubiquitinated, hHR23a may be mono- or
multi-ubiquitinated by BCA2.
14-3-3s and hHR23a are co-expressed in BCA2 positive
breast cancer cell lines
Whole cell lysates from a panel of breast cancer cell lines
were analyzed via Western blotting. Blots were probed to
investigate the endogenous expression of hHR23a, 14-3-
3s and BCA2. BCA2 has been shown to be transcription-
ally up-regulated in ER-positive mammary epithelial cell
lines [2,16], protein expression levels shown in Figure 2A
Table 1 Putative binding partners of BCA2
Gene Accession Number Function
*14-3-3s AF029082 Proliferation, signal transduction and apoptosis
*Human homolog of Rad23 variant A DBJ|BAD9250.1 DNA Repair, chaperone
Atrophin-1 U23851 Transcription factor
CDC2-related protein kinase 10 (CDK10) L33264 Cell proliferation
c-Ha-ras-1 PRF|090402A Cell signalling
Cystatin-C BC013083 Inhibitor of cysteine proteases
Dedicator of cytokinesis 4 (DOCK4) gb|AAI17689.1 Regulates cell-cell adhesion
FOLR3 protein gb|AAH30285.1 Internalization of folic acid
Microfibril-associated glycoprotein 4 BC022666 Cell adhesion & cell-cell interactions
SNC73 protein AF067420 Colorectal cancer marker
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cell lines ZR751, BT474 and MCF7 (Figure 2A, lanes 1-3)
have elevated expression of the BCA2 protein compared
with ER-negative cell line MDA MB 231 (Figure 2A, lane
4). Expression of hHR23a was marginally increased in ER
positive cells as determined by densitometry. Analysis
further showed that BCA2 was upregulated in cells
expressing high amounts of 14-3-3s. The expression of
14-3-3s was variable between cell lines, likely due the
epigenetic regulation of this protein in cancer cells.
From the Western blots of breast cancer cell lines, we
observed that BCA2, 14-3-3s and hHR23a are expressed
in the ER-positive cell line MCF7 (Figure 2A). The cel-
lular localization of these proteins was analyzed through
immunofluorescent staining of endogenous proteins
(Figure 2B and 2C). hHR23a and BCA2 were observed
in the cytoplasmic and nuclear compartments (not
shown). In the cytoplasm BCA2 showed a punctate
staining pattern (Figure 2B, first panel), while hHR23a a
showed a more diffuse staining pattern (Figure 2B, sec-
ond panel). Merged images indicated a large area of co-
expression of BCA2 and hHR23a MCF7 cells (Figure 2B,
last panel). Unlike BCA2, 14-3-3s exclusively localized
to the cytoplasm (Figure 2C, middle panel). In the cyto-
plasmic compartment, significant overlay was noted
between 14-3-3s and BCA2 (Figure 2C, bottom panel).
These data confirmed that not only are these proteins
co-expressed in MCF7 cells, but also that BCA2 co-loca-
lized with both hHR23a and 14-3-3s.
BCA2 and hHR23a expression correlates in breast cancer
tissues
T h ep r e v a l e n c eo fc o - e x p r e s s i o no fB C A 2a n de i t h e r
hHR23a or 14-3-3s was evaluated in multiple breast
cancer cases. Serial sections of two breast cancer tissue
microarrays (TMA) totalling 105 case were were
assessed. TMA immunostaining was visualized with
DAB following probing with antibodies against BCA2,
hHR23a and 14-3-3s. Sections were scored for percen-
tage of cells staining in the cytoplasmic or nuclear com-
partments of cells. An average of the triplicate punches
was used to score each case. Cells were designated as
having nuclear staining, if the nuclear compartment was
significantly darker than the surrounding cytoplasmic
staining, to rule out mis-scoring due to cytoplasm over-
laying the nucleus. Percent abundance of staining as it
pertained to each cellular compartment was defined by
the number of tumor cells which expressed the proteins
in question in each location, independent of expression
of proteins in the other compartments (examples of
Figure 2 Endogenous expression and localization of BCA2 and partner proteins.[ A] Western blot comparing expressed protein levels of
BCA2, hHR23a, 14-3-3s and b-Tubulin in ER-positive and ER-Negative cell lines. Normalized relative intensities of each protein are displayed
below their respective blots. Microscopy images, taken at 100 × magnification, of endogenous IF staining for [B] BCA2 and hHR23a or [C] BCA2
and 14-3-3s, tagged with either secondary antibody conjugated to FITC-dye or Cy3, in MCF7 breast cancer cells. The last panel shows the
merged image and co-localization of the proteins.
Bacopulos et al. BMC Cancer 2012, 12:63
http://www.biomedcentral.com/1471-2407/12/63
Page 6 of 15staining are shown in Figure 3A). Sections were further
scored for the intensity of DAB staining, and were clas-
sified as either 3+, 2+, 1+ or 0 (Figure 3B), correspond-
ing to strong, medium, weak or negative staining
(staining verified by J.Z). Cells were considered to have
low staining if intensity was scored at 0 or 1+ or if 10%
or less of tumor cells were staining. Cores were consid-
ered to be staining highly if more than 10% of tumor
cells were staining at an intensity of 2+ or 3+.
Of the 105 tumors stained with the BCA2 antibody,
97.1% stained positively in the cytoplasm and 60% stained
positively in the nucleus. 93.3% percent of tissues stained
positive for hHR23a in the cytoplasm and 54.3% of tumor
stained positively in the nucleus. 14-3-3s was observed as
exclusively staining in the cytoplasm of tumor cells, and
was scored as positively staining in 61.9% of tissues.
Co-expression of these proteins was analyzed based on
intensity and percent of positive tumor cells. Expression
was again broken down by nuclear and cytoplasmic loca-
lization and analyzed with Fisher’s exact t-Test. Cytoplas-
mic expression of BCA2 was found to correlate
significantly (P = 0.0113) with cytoplasmic hHR23a
expression, where BCA2 is highly expressed in tissues
which highly expressed hHR23a. BCA2 and 14-3-3s did
Figure 3 Immunohistochemistry of breast cancer TMA (n = 105).[ A] An example of how tumors were scored for protein localization. The
top panel is staining positively in the cytoplasm with no nuclear staining, the bottom panel shows a tissue which is staining weakly in the
cytoplasm and stongly in the nuclear compartment. [B] Shows examples of the criteria for staining intensity, where 3+ (top left) has the
strongest staining/most intense and 1+ (top right) which has the weakest staining/least intense. A tissue staining negatively (0), is also shown
(bottom right). [C] Shows a typical staing pattern for a serial section of the same tumor at 5 × magnification and 20 × magnification for BCA2,
hHR23a and 14-3-3s immunostaining, aswell as H&E staining.
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0.0804), however, the numbers trended towards low
levels of 14-3-3s expression in the presence of high
BCA2 expression, 41.9% of 105 tumors. More signifi-
cantly than cytoplasmic correlation between hHR23a,
was the nuclear co-expression. Tissues with low BCA2
also appeared to have low hHR23a, and vice versa, tissues
with high BCA2 expression also had high hHR23a
expression (P = < 0.0001).
BCA2 expression was further analyzed in terms of the
clinical variables Grade, ER status, PR status and HER2
status (Table 2). Grade was the only clinical variable which
showed a statistically significant correlation with BCA2
expression (P = 0.0297). High levels of BCA2 expression
was correlated with a diagnosis of grade 2 breast cancer.
Our study did not show any statistically significant correla-
tion estrogen receptor or progesterone receptor in either
the cytoplasm or the nucleus. However, in the context of
both ER and PR, BCA2 was more likely to be high in posi-
tive cells, 50 cases and 39 cases out of 103 respectively.
Localization of hHR23a was also compared to clinical vari-
ables (Table 2). Cytoplasmic hHR23a correlated with posi-
tive ER expression (P = 0.0181). Moreover, while not
statistically significant, high cytoplasmic hHR23a trends
towards negative nodal status (P = 0.0585).
BCA2 is unstable in the presence of E2s of the UbcH5
family
BCA2 has a very strong autoubiquitination activity in the
presence of the E2 UbcH5b, which resulted in its rapid
degradation [2]. To determine whether other E2s are
involved in BCA2 degradation, HEK293T cells were co-
transfected with expression vectors for E2 enzymes
UbcH5a, UbcH5b, UbcH5c, or Ubc3 as well as GST-
BCA2 or ligase-dead GST-BCA2 RING mutant. Western
blot analysis showed that in the absence of E2, both the
wild-type BCA2 and RING mutant are visible when
probed with anti-GST antibodies (Figure 4A lanes 1 and
2, top panel). However, in the presence of enzymes of the
UbcH5 family, wild-type BCA2 was degraded and there-
fore undetectable by immunoblot (Figure 4A, lanes 3-8,
top panel). The RING-mutant expression was maintained
under these conditions due to its abrogated autoubiquiti-
nation activity. Both BCA2 and RING mutant were
strongly expressed in the presence of Ubc3 (Figure 4A,
lanes 9 and 10, top panel). This suggested that Ubc3 had
no effect on the degradation of BCA2 (Figure 4A, lanes 9
and 10, top panel).
hHR23a inhibits BCA2 autoubiquitination activity and
stabilizes BCA2
In its role as an ubiquitin receptor, hHR23a is known to
prevent the formation of polyubiquitin chains, and thus
inhibits degradation of target proteins [22,23]. The effect
of hHR23a on BCA2 polyubiquitin chain formation was
examined through Ubiquitination assays. HEK293T cells
were co-transfected with BCA2 and Ubiquitin expres-
sion vectors; along with hHR23a and/or UbcH5b. Fol-
lowing immunoprecipitation (IP) of BCA2, we observed
intense, high molecular weight ubiquitination smears
Table 2 Expression of BCA2 and hHR23a in breast cancer cases
Cytoplasmic BCA2 Nuclear BCA2 Cytoplasmic hHR23a Nuclear hHR23a
Variable Low (%) High (%) P-value Low (%) High (%) P-value Low (%) High (%) P-value Low (%) High (%) P-value
ER
Positive 27 (34.2) 52 (65.8) 0.8053 29 (36.7) 50 (63.3) 0.4772 27 (34.2) 52 (65.8) *0.0181 39 (50.0) 39 (50.0) 0.4947
Negative 7 (29.2) 17 (70.8) 11 (45.8) 13 (54.2) 2 (8.3) 22 (91.7) 10 (41.7) 14 (58.3)
PR
Positive 17 (31.3) 39 (68.7) 0.6743 17 (30.4) 39 (69.6) 0.0686 19 (33.9) 37 (66.1) 0.1897 26 (47.3) 29 (52.7) 1.000
Negative 17 (36.1) 30 (63.9) 23 (48.9) 24 (51.1) 10 (21.3) 37 (78.7) 23 (48.9) 24 (51.1)
HER2
Positive 6 (35.3) 11 (64.7) 1.000 8 (47.1) 9 (52.9) 0.5878 5 (29.4) 12 (70.6) 1.000 10 (58.8) 7 (41.2) 0.4292
Negative 28 (32.9) 57 (67.1) 32 (37.6) 53 (62.4) 23 (27.1) 62 (72.9) 39 (46.4) 45 (53.6)
Grade
1 2 (22.2) 7 (77.8) 0.5501 4 (44.4) 5 (55.6) * 0.0297 3 (33.3) 6 (66.7) 0.2730 5 (55.6) 4 (44.4) 0.4142
2 18 (38.3) 29 (61.7) 12 (25.5) 35 (74.5) 14 (29.8) 33 (70.2) 19 (41.3) 27 (58.7)
3 14 (30.4) 32 (69.6) 24 (52.5) 22 (47.8) 12 (26.1) 34 (73.9) 25 (54.3) 21 (45.7)
Nodal
Positive 11 (32.4) 23 (67.6) 1.000 10 (29.4) 24 (70.6) 0.1952 14 (41.2) 20 (58.8) 0.0585 17 (51.5) 16 (48.5) 0.6649
Negative 20 (33.3) 40 (66.7) 26 (43.3) 34 (56.7) 13 (21.7) 47 (78.3) 27 (45.0) 33 (55.0)
* Indicates a correlation which is statistically significant by Fisher’s exact t-test or c
2 test
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characteristic of BCA2 autoubiquitination [7]. Ubiquitin-
laddering was present when BCA2 was expressed alone
(Figure 4B lanes 1 and 2), or with UbcH5b where BCA2
auto-ubiquitination increased. However, when hHR23a
was co-expressed in the system, the BCA2 ubiquitina-
tion smear dramatically diminished or was undetectable
(Figure 4B, lanes 3 and 4). This suggested that hHR23a
acts as an inhibitor of BCA2 autoubiquitination ability
by abrogating multi-ubiquitin chain elongation.
To further investigate the outcome of the interaction
between BCA2 and hHR23a, HEK293T cells were co-
transfected with a constant concentration of BCA2 or
BCA2 RING mutant and an increasing concentration of
hHR23a plasmid DNA (0 μg-2 μg) (Figure 4C). Western
blots were analyzed for relative intensity of BCA2 protein
levels, normalized to b-Tubulin. We observed a positive
correlation between elevated BCA2 expression and
increased hHR23a concentration. Up to 130-fold increase
was evident with 2 μg of hHR23A, as compared with no
hHR23A expression. There was no significant change
observed for BCA2 RING mutant protein expression in
the presence of hHR23a. This indicated that hHR23a sta-
bilized BCA2 in a dose dependent manner.
Figure 4 hHR23a rescues and stabilizes BCA2 from UbcH5 mediated poly-ubiquitination.[ A] Immunoblots of lysates from HEK293T cells
cotransfected with GST-tagged BCA2 (GST-BCA2) and BCA2 with the RING domain mutation C228/231A (GST-BCA2-RING mt) and/or expression
vectors for His-tagged Ubc3 and UbcH5a/b/c as indicated. [B] Western blots of HEK293T cells which were co-transfected with stable amounts of
either GST-tagged wild-type BCA2 or GST-BCA2 RING mt along with an increasing amount of myc/his-hHR23a. Relative intensity of BCA2
normalized to b-Tubulin is given below the blot as fold change compared to lanes 1 and 5 respectively. [C] Immunoblot showing lysates of in
vivo ubiquitination assay probed with anit-HA following immunoprecipitation of Flag-BCA2 with anti-FLAG antibodies. HEK293T cells were co-
transfected with HA-ubiquitin, and FLAG-BCA2 along with either myc/his-UbcH5b or myc/his-hHR23a or both as indicated above lanes. [D]
Immunoblot of a half-life assay of HEK293T cells transfected with GST-BCA2 with and without myc-hHR23a. Cells were treated over a 24 hours
time course with cyclohexamide. Relative intensity of BCA2 normalized to b-Tubulin is given below the blot as fold change.
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4C showed that hHR23a increased the stability of BCA2
through the inhibition autoubiquitination. Stabilization of
BCA2 by hHR23a was further examined through half-life
assays, HEK293T cells were co-transfected with hHR23a
and BCA2 and protein extracts were harvested at 1, 6, 12
and 24 hours time points following addition of CHX or
DMSO. Protein expression was and compared via western
blot (Figure 4D). BCA2 protein level diminished more
rapidly in the absence hHR23a in CHX-treated cells. Con-
d i t i o n sw h e r eB C A 2w a sc o - e x p r e s s e dw i t hh H R 2 3 a
exhibited less degradation of BCA2 over time. DMSO con-
trol treatments (data not shown) indicated that the effects
observed was a result hHR23a. These data suggested that
BCA2 half-life was increased upon interaction with
hHR23a.
14-3-3s binds BCA2 through interaction with its
phosphorylated AKT domain
Protein phosphorylation is arguably the most common
covalent modification of proteins, and induces changes to
conformation and stability [24]. BCA2 was shown to be
phosphorylated in the AKT domain [8]. To investigate the
role of phosphorylation on BCA2 stability, HEK293T cells
were co-transfected with a constitutively active variant of
AKT or a kinase-dead AKT mutant, along with FLAG-
tagged BCA2 (Figure 5A, lanes 1 and 2) or the S132, 133A
mutant which abolished AKT phosphorylation (Figure 5A,
lanes 3 and 4). Figure 5A showed that wild-type BCA2 is
stabilized by the addition of constitutively active AKT
(lane 2) compared with BCA2 kinase-dead AKT (lanes 1
and 3). Furthermore, there was no change in the expres-
sion of the BCA2 S132, 133A mutant [7]. This indicated
that post-translational modification of BCA2 is necessary
to its regulation.
In silico analysis of BCA2 revealed that AKT domain
contains 14-3-3 binding sequences. Immunoprecipitations
(Figure 5B) of lysates co-expressing BCA2 and 14-3-3s
indicated that 14-3-3s co-immunoprecipitated with the
wild-type BCA2 with greater affinity than with the S132,
133A mutant (lanes 1 and 3). Moreover, when treated
with AKT-kinase inhibitor LY294002 (Figure 5B, lane 2),
14-3-3s bound to wild-type BCA2 with lesser affinity
compare to untreated wild-type BCA2 lysate or the
untreated S132, 133A lysate. Together these data sug-
gested that the phosphorylation of BCA2 by AKT was
important to partner interaction.
BCA2 is stabilized by substrate interactions with 14-3-3s
Some E3 ligases have been known to be stabilized by sub-
strate interaction. We assayed the ability of 14-3-3s to
affect the stability of the BCA2 protein. HEK293T cells
co-expressing Xpress-14-3-3s and wild-type Flag-BCA2
were incubated with protein degradation inhibitor MG-
132 (Figure 5C) or DMSO control. Lysates in which wild-
type BCA2 was expressed alone showed decreased levels
of BCA2 protein though immunobloting compared to
samples where BCA2 was co-expressed with 14-3-3s
(Figure 5C). This was observed both in the presence and
the absence of MG-132. These data suggested that BCA2
was stabilized more by expression of partner proteins
than by inhibition of protein degadation. Moreover, the
experiment further indicated that 14-3-3s is a substrate
for BCA2 as 14-3-3s expression decreased upon the
expression of BCA2.
Discussion
An integral component of understanding E3 ligase func-
tion is identifying the enzyme’s cognate substrate(s) and/
or binding proteins. Previous binding partners of BCA2
included Rab7, isolated through yeast-II-hybrid screening
[17], tetherin, which was found though brute-force GST-
pulldowns [18], and ubiquitin and UBC9 from bacteria-II-
hybrid screening [7,16]. Bacteria and yeast screening
systems were used in this study to identify additional
potential binding partners of BCA2 (Table 1). Of the
potential partners found, 14-3-3s and hHR23a were cho-
sen for further investigation in the context of BCA2 activ-
ity and expression. Through binding experiments we
confirmed that the BCA2 protein bound both to 14-3-3s
and hHR23a (Figure 1B and 1C). hHR23a and BCA2 were
co-expressed in a mammalian system, while 14-3-3s was
expressed in a bacterial system and incubated with recom-
binant purified BCA2. The expression levels of wild-type
BCA2 and the S132, 133A mutant in HEK293T cells were
much lower than those of the RING-mutant and BZF
mutant, which is a possible confounding factor in deter-
mining domains necessary for binding hHR23a. The over-
expression of BZF and RING mutants likely resulted from
steric hinderance of BCA2 autoubiquitination activity
from the GST-expression tag. Both the wild-type BCA2
protein and the RING mutant, but not the BZF or S132,
133A mutants of BCA2 were pulled down by 14-3-3s,
indicating that sequences in the BZF domain or AKT
domain may be necessary for interaction.
P r o t e i ni n t e r a c t i o nw a sc o n f i r m e di na ne n d o g e n o u s
system. Breast cancer cell lines were probed for expres-
sion of hHR23a and 14-3-3s, along with BCA2 (Figure
2A). BCA2 has previously been reported as co-expres-
sing with estrogen receptor [2,16], thus high expression
was expected in ER-positive cell lines ZR751, BT474
and MCF7, while lower expression was expected in the
ER-negative cell line MDA MB 231. Our findings were
consistent with these expectations. hHR23a was
expressed in all cell lines, but had slightly higher expres-
sion in the ER-positive cell lines, which correlated with
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TMAs. Immunofluorescence studies confirmed that
endogenous proteins co-localized.
Protein expression was further investigated in the con-
text of breast cancer analyzed though IHC. Tumor cores
which stained highly positive for BCA2 also stained
highly positive for hHR23a in both the nucleus and the
cytoplasm. This correlation was determined to be signif-
icant by Fisher’s Exact T-Test. From this we inferred
that not do these proteins interact, but they are co-
expressed endogenously in the same cells and tissues.
While not statistically significant, in the tumors BCA2
and 14-3-3s trended towards an inverse relationship in
expression. The majority of samples which stained
highly for BCA2 were scored as having low expression
of 14-3-3s.
A problem which emerged over the course of studying
B C A 2 ,w a st h eu n s t a b l en a t u r eo ft h ep r o t e i nd u et o
intrinsic autoubiquitination activity. Initial investigations
of BCA2 stability, found that degradation via autoubi-
quitination was equally possible with all UbcH5 family
members, but not with other E2’ss u c ha st h eU b c H 3
Figure 5 AKT mediated phosphorylation leads to an increase in BCA2 stability through 14-3-3s interaction.[ A]I m m u n o b l o to fe q u a l
amounts of lysates of HEK293T cells co-transfected with wild-type GST-BCA2 or GST-BCA2 S132, 133A along with either dominant negative or
constitutively active AKT. [B] Co-immunoprecipitation of wild-type BCA2 and 14-3-3s in the presence (lane2) or absence (lanes 1, 3) of AKT
inhibitor LY294002 and co-immunoprecipitation of S132, 133A BCA2 and 14-3-3s.[ C] Western blot showing the results of a stability assay in the
presence of absence of MG-132 on lysates of HEK293T cells which had been tranfected with either wild-type FLAG-BCA2, Xpress-14-3-3s or
both.
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of members of the UbcH5 family was responsible for
the rapid and complete degradation of wild-type BCA2
protein in vitro and in vivo (Figure 4A) [2,7].
As a molecular chaperone, hHR23a regulates the life-
span of its binding partners in both agonisticly and antag-
onistically. In the proteasome system, hHR23a acts as a
shuttle to the proteasome, by simultaneously binding both
the target protein and the lid of the 26 s proteasomal sub-
unit. In contrast to this function, hHR23a also regulates
protein half-life through sequestering nascent ubiquitin
moieties in the emerging polyubiquitin chain. Thereby
preventing chain elongation and de-ubiquitinase activity
and stabilizing the targeted protein [25]. This dual nature
of hHR23a is largely due to the presence of its N-terminal
Ubiquitn-Like domain (UBL) and two C-terminal Ubiqui-
tin-Associating (UBA) domains [26]. The UBL domain
m a yb eak e yc o m p o n e n to fh H R 2 3 a ’s interaction with
BCA2. The significance of this interaction is such that it
increases the stability of BCA2. Increased concentration of
the partner protein correlated with the elevated levels of
BCA2 protein (Figure 4C). We inferred that BCA2 was
stabilized through the prevention of ubiquitin chain elon-
gation by hHR23a (Figure 4B). This was consistent with
reported behaviour of hHR23a as an ubiquitin receptor.
These observations were strengthened since hHR23a was
also shown to increase the half-life of BCA2 over a 24
hours time period (Figure 4D). hHR23a was not a sub-
strate for BCA2-mediated degradation (Figure 1E). This
does not exclude hHR23a mono- or multi-ubiquitination
from being catalyzed by BCA2. Figure 4E showed an
increased stability of hHR23a in the presence of high
BCA2 expression, which may result from ubiquitin modifi-
cation of hHR23a, which has been previously reported
[22,27]. Taken together, data presented here argues that
hHR23a presence may be necessary to modulate and regu-
late BCA2 in a cancer setting.
As well as through interaction with hHR23a, BCA2 was
also increased through modification by AKT phosphoryla-
tion. Phosphorylation has far reaching consequences for
the modified proteins, amoung them are conformational
changes which effect substrate affinity and specificity
[28,29]. It had been previously demonstrated that BCA2
was phosphorylated in the presence of AKT [8]. Here, we
showed that BCA2 was more stable when co-expressed
with constitutively active AKT as opposed to kinase-dead
AKT. The S132, 133A mutant displayed no notable
change in stability. This confirmed that these serine resi-
dues are the primary sites of AKT-mediated BCA2 phos-
phorylation. Surrounding S132 and S133 are two 14-3-3s
binding motifs. The 14-3-3s motif R(S/X)XpSXP [30] is
highly similar to the BCA2 protein sequence 130-
RGSSRP-135 (Figure 1A). 14-3-3s is a member of the ubi-
quitously expressed 14-3-3 family of proteins. The seven
proteins of this family are highly conserved and integral to
a number of important cellular activities. Specifically, 14-
3-3s is known to be a conspicuous regulator of cell cycle
checkpoints, as well as being involved in multiple and
diverse cellular pathways through interactions with its
copious number of known ligands [20,31-33]. We demon-
strated that phosphorylation was an integral element of
the interaction between BCA2 and 14-3-3s.I ns a m p l e s
where the AKT domain of BCA2 was disrupted or where
wild-type BCA2 was treated with AKT inhibitor, BCA2
was less apt to bind 14-3-3s. However, since interaction
between 14-3-3s and BCA2-S132, 133A was not comple-
tely abolished, it is likely that a second functional AKT-
phosphorylation site and 14-3-3s binding site exists. We
predicted this site to be in the adjacent sequence, 133-
SRPDRSPS-140 (Figure 1A).
Similar to hHR23a, the outcome of interaction of BCA2
with 14-3-3s was an increase in BCA2 stability. Presump-
tively, BCA2 is stabilized as 14-3-3s sterically or confor-
mationally prevents access of the RING finger domain to
the target lysines (K26 and K32) in the BZF domain [7].
More than stabilizing BCA2, this interaction decreases the
protein levels of 14-3-3s (Figure 1D). This effect was not
seen when the same experiment was repeated with
hHR23a. hHR23a levels did not decrease with the increase
in BCA2 (Figure 1E), suggesting that 14-3-3s but not
hHR23a is a substrate of BCA2. Other E3 ligases that have
been demonstrated to be stabilized by the binding of their
substrate include HOS (homologue of Slimb), where pre-
sence of substrate IBa stabilized HOS turnover [34].
Another examples being Cdc 4 (cell division cycle 4),
which binds ubiquitin to promote its own degradation in
the absence of substrate, as the binding of ubiquitin and
substrate are mutually exclusive events. However when
substrate is present, Cdc4 is stabilized, suggesting that
substrate concentration is a method of E3 regulation [35].
Moreover, the lack of considerable stabilization by the pre-
sence of a proteasome inhibitor alone, provides basis for
the argument that BCA2 may not be solely degraded in a
proteasome-mediated pathway, but may be regulated by
other pathways, such as the lysosomal degradation path-
way, similar to c-Cbl, which auto-regulates and is
degraded via the lysosome [36-38].
Pharmacological pursuits in the area of cancer thera-
pies have in the past been aimed at the non-specific com-
ponents of the UPS. The most effective and promising of
these therapeutics is Bortezomib (Velcade™), which inhi-
bits the chymotryptic activity of the proteasome [39,40].
As the components of the UPS are arranged in a pyrami-
dal way, with few E1 enzymes at the top and multiple
and specific E3 ligases at the base, they make attractive
and optimal components for study and potential thera-
peutic targeting. In this study, BCA2 was analyzed in the
context of its expression in breast cancer tissues and the
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expression and variables considered being of diagnostic
and prognostic value. Of the patient attributes analyzed,
only grade had a statistically significant correlation with
nuclear BCA2 expression, such that a mid- level (2)
Grade classification was correlated with high BCA2
expression in the nucleus. Along with previous studies
which correlated overall increased BCA2 expression with
ER-positive status, negative nodal status and increased
survival over 5 years [2]; it is more likely that BCA2 is
indirectly involved in progression of breast cancer to
highly invasive and metastatic disease, rather than a dri-
ver of the process. Moreover, when hHR23a expression
was analyzed against the same attributes, it was found
that hHR23a correlated with ER-positive status, a correla-
tion which had been found previously with BCA2 in a
large scale (n = 1000) [2]. Also while not statistically
significant, it is noteworthy that in a majority of samples,
high hHR23a expression occurred in cases which were
negative for lymph node status. This clinical variable was
found to have correlated with high BCA2 in our previous
studies [2]. The small number of significant correlations
in this study may be due to the relatively small sample
population, as greater emphasis is placed on individual
anomalies and deviations. As ligases can be of both
tumor suppressive and oncogenic natures, in order to
evaluate E3s or their substrates in the context of cancer
therapeutics and prognostics; an understanding of the
mechanisms in which they are deregulated and/or stabi-
lized is essential.
Conclusion
The regulation mechanisms of E3 ligases are still veritable
“black boxes”. Reviewed by de Bie and Ciechanover [15],
Figure 6 Model for BCA2 stability.[ A] BCA2 in the presence of specific E2, but in the absence of binding partner or substrate is targeted to the
proteasome for degradation through auto-ubiquitination in the BZF domain (as shown in Figure 2). [B] Depicts the potential interaction between
BCA2 and hHR23a. We speculate that the ubiquitin-like (UBL) domain of hHR23a binds to the ubiquitin-binding domain (BZF) of BCA2, which not
only leads to protein stabilization but also plays a role as a scaffold for ubiquitination of other substrates to aid BCA2 in its role as an E3 ligase. [C]
14-3-3s binds BCA2 in the AKT phosphorylation domain which contains two 14-3-3 binding motifs, the result of binding is possible steric inhibition
of the autoubiquitination of BCA2, leaving the RING domain of BCA2 available to facilitate the conjugation of ubiquitin to 14-3-3s.
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substrate affinity and ubiquitination are controlled. c-Cbl,
a RING-type E3 responsible for the internalization and
degradation of EGFR, has been found to be activated to a
ubiquitination-capable state by phosphorylation [41].
Moreover, dynamic mono-ubiquitination or non-K48
linked multi- and branched multi-ubiquitin chains, can
also either increase the stability of the E3 ligase or change
its ability to bind substrate as is the case with E3 ligases
RING1B and histone H2A [42,43]. But largely, the most
observed method of E3 regulation, or deregulation, is pro-
teolytic targeting through auto-ubiquitination. It has been
observed in many E3 ligases that the presence of substrate
or other interacting partners inhibit and attenuate the pro-
teins self-destructive activity [44]. Interestingly, E3 ligases
interact with other components of the ubiquitin protea-
some system often with proteins that have antagonistic
roles. One such example is ICP0, a RING-type E3 ligase
which stimulates lytic infection of Herpes Simplex virus-1.
Upon binding the de-ubiquitinase USP7, the ability of
ICP0 to auto-ubiquitinate is counteracted, and is subse-
quently unable to target itself for degradation and thus sta-
bilized [44]. In other instances, E3 ligases form
heterodimers, such as BRCA1/BARD1 or LMP-1 and
TRAF3. Such interactions may have functional conse-
quences; they also result in the stabilization of the inter-
acting E3’s and prevent auto-ubiquitination, as is the case
of LMP-1 [45]. From the experiments performed in this
study and knowledge of how other E3 ligases respond to a
similar problem with inherent protein stability, we propose
the following model for the likely behavior of BCA2 (Fig-
ure 6). In the absence of a binding partner or substrate
protein, BCA2 likely catalyzes its own ubiquitination,
where the RING domain facilitates the addition and elon-
gation of ubiquitin chain to the known accepting lysines in
the BZF domain [7] (Figure 6A). When a target or inter-
acting protein such as hHR23a binds, likely in the BZF
domain, and results in the inhibition of autoubiquitination
activity which in turn stabilizes the BCA2 E3 ligase (Figure
6B). This interaction prolongs BCA2 half-life and would
then allow for the ubiquitination of a substrate, or incor-
poration into a complex. Due to the affinity of the BZF
domain to ubiquitin, a confirmed binding protein, and
also to UBA52 [7], a ubiquitin fusion protein, we propose
that a substrate for BCA2 may be previously mono-ubiqui-
tinated or containing a ubiquitin like-domain. In the case
of 14-3-3s, the interaction between phosphorylated BCA2
and 14-3-3s, prevents self-ubiquitin conjugation by BCA2,
and results in the catalysis of poly-ubiquitin chain forma-
tion and elongation on 14-3-3s, followed by degradation
(Figure 6C).
Our previous work found BCA2 expression correlates
with positive estrogen receptor status, negative lymph
node status with an increase in disease-free survival for
regional recurrence. In this study we found that hHR23a
is also correlated with ER-positive status and trends
towards negative nodal status. Now we have found that
high BCA2 levels, specifically in the nucleus also corre-
lates with tumor grade, and that the ability of BCA2 to
be up-regulated is likely due to presence of hHR23a or
14-3-3s. Together these clinical associations indicate
that the mechanisms of BCA2 regulation may be impor-
tant to the physiology of breast carcinogenesis and
growth, as well as the predictability of tumor response
to treatment.
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